LivingGLP1
Study S000353

A Randomized-Controlled Trial of Semaglutide for Patients With Chronic Low Back Pain and Obesity

ClinicalTrials.gov record

Registration

Registration
NCT07731256
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2
Masking
QUADRUPLE
Status
NOT_YET_RECRUITING
Enrollment
250
Start
2027-02-01
Primary completion
2031-01-01
Lead sponsor
Washington University School of Medicine
Conditions
Lower Back Pain; Obesity (BMI>30); Chronic Lower Back Pain; glp1 Agonist
Interventions
DRUG:Semaglutide (administered by PDS290 pen-injector); DRUG:Placebo (administered by PDS290 pen-injector)
Results posted
FALSE
Individual participant data sharing
YES

Registered primary outcomes

  • BPI-SF Pain Severity Scale [Baseline, up to 52 weeks]

Linked records (7)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0002918Mapping the effectiveness and risks of GLP-1 receptor agonists.
Xie Y, Nature medicine
2025Nonrandomized studyPMID 39833406DOIregistry reference BACKGROUND:39833406
R0003306Advances in GLP-1 receptor agonists for pain treatment and their future potential.
He Y, The journal of headache and pain
2025Narrative reviewPMID 40016636DOIregistry reference BACKGROUND:40016636
R0003357Glucagon-Like Peptide-1 Receptor Agonists and Osteoarthritis.
Felson DT, The New England journal of medicine
2024CommentaryPMID 39476345DOIregistry reference BACKGROUND:39476345
R0007372Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
Bliddal H, The New England journal of medicine
2024Randomized trialPMID 39476339DOIregistry reference BACKGROUND:39476339
R0018212Dual effects of dulaglutide on glycemic control and knee osteoarthritis pain in elderly patients with Type 2 diabetes.
Samajdar SS, Pain management
2024OtherPMID 39301951DOIregistry reference BACKGROUND:39301951
R0008662Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Garvey WT, Lancet (London, England)
2023Randomized trialPMID 37385275DOIregistry reference BACKGROUND:37385275
R0009553Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
Wharton S, The New England journal of medicine
2023Randomized trialPMID 37351564DOIregistry reference BACKGROUND:37351564